Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Can massive parallel sequencing replace fluorescent in situ hybridization for detection of fusion genes in patients with non-small cell lung cancer?
Örebro University, School of Health Sciences.
2017 (English)Independent thesis Advanced level (degree of Master (Two Years)), 20 credits / 30 HE creditsStudent thesis
Abstract [en]

Abstract

Today the golden standard method to find fusion genes is with fluorescent in situ hybridization. Massive parallel sequencing is a method that can analyze several genes and samples at the same time at a lower cost. The aim of this study was to compare massive parallel sequencing with fluorescent in situ hybridization for detection of fusion genes in patients with non-small cell lung cancer. Additionally, an evaluation of RNA extraction was performed to obtain RNA samples with quality. Four different purification methods were evaluated and method C, a semi-automatic method showed the highest quantity and a good quality. Method C was used to extract 23 samples from non-small cell lung cancer patients and analyzed with massive parallel sequencing and panel Oncomine Solid Tumour Fusion Transcript Kit (Thermo Fisher Scientific). A total of 11/14 samples showed concordant results with fluorescent in situ hybridization. Three samples either had too low quality or there was too little tissue left on the FFPE block to determine the tumor cell content. Unfortunately, there is a shortage of positive fusion genes samples since the qualities of the samples were uncertain and especially the proportion of tumor cells. No conclusion can be drawn if massive parallel sequencing can replace fluorescent in situ hybridization in the future for patients with non-small cell lung cancer. Further studies are required.

Place, publisher, year, edition, pages
2017.
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:oru:diva-58607OAI: oai:DiVA.org:oru-58607DiVA: diva2:1120849
Subject / course
Biomedicinsk laboratorievetenskap
Available from: 2017-07-07 Created: 2017-07-07 Last updated: 2017-10-18Bibliographically approved

Open Access in DiVA

fulltext(261 kB)39 downloads
File information
File name FULLTEXT01.pdfFile size 261 kBChecksum SHA-512
41445b844715b78ab93b96a3ac84311a4bec44d63e7ad29b6265a8f8fe8264973f55084ed21642a41cd690771f237960a6ae80650f9d1d48b53207fa35004e86
Type fulltextMimetype application/pdf

By organisation
School of Health Sciences
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 39 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

urn-nbn

Altmetric score

urn-nbn
Total: 128 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf